Results 51 to 60 of about 740 (167)

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN

Hematology, Transfusion and Cell Therapy, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggressive clinical course and poor prognosis. BPDCN is most often characterized by its presentation with cutaneous lesions which are often asymptomatic, can be
Hanan Hamed
doaj   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor

, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive primary cutaneous lymphoma characterized by transformed plasmacytoid dendritic cells that overexpress interleukin-3 receptor subunit alpha (IL3RA) also known as CD123.
Egger, Andjela, Coello, Diana, Kirsner, Robert S, Brehm, Julia Escandon   +3 more
core   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies

Cells
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with poor outcomes. The World Health Organization (WHO) redefined BDCN as a distinct disease entity in 2016. BPDCN arises from plasmacytoid dendritic cells,
Shefali Mehra, Justin Taylor
doaj   +1 more source

Cutaneous involvement by myeloid leukaemias: challenging cases with important implications

Histopathology, EarlyView.
Myeloid leukaemias and precursors involving the skin are often challenging to diagnose with varied and overlapping clinical and histopathologic features. Nonetheless, they are critical for pathologists to recognize and accurately classify. This review discusses the clinical, histopathological and genetic features of myelodysplasia cutis (A) and ...
Alexandra C. Hristov
wiley   +1 more source

NEOPLASIA DENDRÍTICA PLASMOCITÓIDE BLÁSTICA EM PACIENTE PEDIÁTRICO

Hematology, Transfusion and Cell Therapy, 2023
Objetivo: Relatar uma doença rara em faixa etária atípica. Materiais e métodos: Os dados deste trabalho foram obtidos de revisão de prontuário e revisão da literatura.
BL Souza, AM Carvalho, JF Lopes, MG Duarte, MJS Vasconcelos, MM Dias, WWF Costa, ACB Bomfim, WGG Fischer, PR Fonseca   +9 more
doaj   +1 more source

Accelerating Pediatric Oncology Drug Development: Advances in Clinical Pharmacology, Trial Design, Non‐Clinical Evidence, and Regulatory Science

The Journal of Clinical Pharmacology, Volume 66, Issue 7, July 2026.
Abstract Pediatric oncology drug development remains uniquely challenging due to the rarity and biological heterogeneity of childhood cancers, ethical considerations in trial conduct, and the limited feasibility of large, randomized studies. Despite these barriers, recent years have seen a notable acceleration in the approval of oncology therapies for ...
Ya‐Feng Wen, Xiaoning Wang, Sarandeep Boyanapalli, Lee Anderson, Thao Dang, Guan Xing, Marianna Calvet, Tiffany Hart, Sreeneeranj Kasichayanula, Xiaochen Zhao   +9 more
wiley   +1 more source

NEOPLASIA DE CÉLULAS DENDRÍTICAS PLASMOCITÁRIAS BLÁSTICAS: RELATO DE CASO

Hematology, Transfusion and Cell Therapy, 2023
Introdução: A neoplasia de células dendríticas plasmocitárias blásticas (NCDPB) é uma neoplasia hematológica rara e agressiva, que se manifesta como lesões cutâneas com ou sem envolvimento da medula óssea e disseminação leucêmica.
NM Bernardes, WSV Júnior, LMB Batista, SEBJ Neves, SS Custodio, TG Teixeira, TV Lourenço, RG Silva, ABF Glória, FL Nogueira   +9 more
doaj   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source